indication
as of 2026-07-01Child Development Disorders, Pervasive
Competitive landscape projected to LB-102’s launch window
Competitive set
1
1 approved · 0 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047
Projection timeline
actual past → guided future · protection walls overlaid
25 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugCompleted
US-approved 2010 · Latuda
Phase 21 trial
Protection2031
Market size
prevalence as a range, not a number